Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Equity (2016 - 2025)

Historic Return on Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.43%.

  • China Pharma Holdings' Return on Equity rose 2500.0% to 0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43%, marking a year-over-year increase of 2500.0%. This contributed to the annual value of 0.62% for FY2024, which is 1000.0% down from last year.
  • As of Q3 2025, China Pharma Holdings' Return on Equity stood at 0.43%, which was up 2500.0% from 0.54% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Return on Equity registered a high of 0.39% during Q1 2021, and its lowest value of 1.12% during Q4 2022.
  • Over the past 5 years, China Pharma Holdings' median Return on Equity value was 0.59% (recorded in 2023), while the average stood at 0.64%.
  • As far as peak fluctuations go, China Pharma Holdings' Return on Equity skyrocketed by 19900bps in 2021, and later tumbled by -5900bps in 2022.
  • China Pharma Holdings' Return on Equity (Quarter) stood at 0.53% in 2021, then crashed by -111bps to 1.12% in 2022, then surged by 59bps to 0.45% in 2023, then tumbled by -46bps to 0.66% in 2024, then soared by 35bps to 0.43% in 2025.
  • Its Return on Equity was 0.43% in Q3 2025, compared to 0.54% in Q2 2025 and 0.62% in Q1 2025.